Top Markets
#1 Islamic Coin Islamic Coin +151.57%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.99%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.03%
#4 clBTC clBTC +12.26%
#5 OpenEden OpenEden +10.90%
#6 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.95%
#7 MarsCoin MarsCoin +8.78%
#8 Mantle Staked Ether Mantle Staked Ether +8.43%
#9 Mantle Restaked ETH Mantle Restaked ETH +8.23%
#10 Akedo Akedo +8.03%
Coin of the day
Islamic Coin Islamic Coin
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Cyxone AB (publ) Cyxone AB (publ)

Cyxone AB (publ)

CYXO
Rang in aandelen #40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.
Aandeelprijs
$0.00162013
Laatst gesynchroniseerd: 2025-01-03
Marktkapitalisatie
$156.25K
Verandering (1 dag)
0.36%
Verandering (1 jaar)
0.00%
Land
SE
Handel Cyxone AB (publ) (CYXO)

Categorie

Healthcare
P/B-ratio voor Cyxone AB (publ) (CYXO)
P/B-ratio op August 2026 TTM: 0.05
Volgens de meest recente financiële rapporten en aandelenkoers van Cyxone AB (publ) is de huidige P/B-ratio (TTM) 0.05. Eind 2022 had het bedrijf een P/B-ratio van 0.95.
P/B-ratiohistoriek voor Cyxone AB (publ) van 2015 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
2026 (TTM) 0.05 -80.68%
2023 0.25 -73.81%
2022 0.95 -62.04%
2021 2.50 -27.47%
2020 3.45 49.69%
2019 2.31 74.16%
2018 1.32 -75.84%
2017 5.48 22.16%
2016 4.49 -98.16%
2015 243.41 0.00%
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 12,863.35%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 13,043.48%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 7,423.81%
BE